Recent Developments in Migraine Treatment Space

• In November 2025, AEON Biopharma, Inc. announced the first closing of its previously announced private placement (“PIPE”). Additionally, the Company announced that the US Food and Drug Administration (the “FDA”) has proposed a new date of January 21, 2026 for AEON's Biosimilar Biological product Development (BPD) Type 2a meeting. The meeting had previously been scheduled for November 19, 2025.
• In October 2025, AEON Biopharma, Inc. announced that the US Food and Drug Administration (FDA) has scheduled a Biosimilar Biological Product Development (BPD) Type 2a meeting for ABP-450 on November 19, 2025, in line with prior guidance.
• In February 2025, Miist Therapeutics, announced USD 7M in seed funding from investors including Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First, and California Innovation Fund, among others. Miist has clinically validated its approach and is currently advancing two assets: MST-01 for the treatment of smoking addiction and MST-02 for the treatment of migraine. With this funding, the company is now positioned to accelerate its assets one step closer to the nearly 100 million patients who need them globally.
• In January 2025, Nuvie Bio, announced completion of a first-in-human trial with NVI-100, the company's lead investigational drug for the acute treatment of migraine.
• In September 2024, Biohaven Ltd. announced that it has initiated a pivotal Phase II study of the potential first-in-class, orally administered TRPM3 antagonist, BHV-2100, in the acute treatment of migraine.
• In May 2024, Pulmatrix announced publication of, "Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase I randomized, double-blind study in healthy adults" in the peer-reviewed publication Headache: The Journal of Head and Face Pain.
• In May 2024, AEON Biopharma, Inc. announced that the preliminary top-line results from its planned interim analysis of the Phase II trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.

Scope of the Migraine Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Therapeutics Assessment By Mechanism of Action: Serotonin 1B receptor agonists, Serotonin 1D receptor agonists, Acetylcholine inhibitors, Glutamate antagonists, Membrane transport protein modulators, Neuromuscular blocking agents, Pituitary adenylate cyclase-activating polypeptide receptor antagonists, Opioid delta receptor agonists, 5-HT2C serotonin receptor antagonists, Serotonin 1F receptor partial agonists, Serotonin 2B receptor antagonists, Serotonin 5-HT2A receptor antagonists, Serotonin 7 receptor agonists, Serotonin-1D-receptor partial agonists
• Key Migraine Companies: Merz Therapeutics, H. Lundbeck A/S, Biohaven, Ipsen, Kallyope Inc., Pulmatrix, AEON Biopharma, Trevena, Nuvie Bio, Miist Therapeutics, Galt Pharmaceuticals, and others.
• Key Migraine Pipeline Therapies: Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents, Pituitary adenylate cyclase-activating polypeptide receptor antagonists, Opioid delta receptor agonists, and others.

Migraine Drugs

Table of Contents

1.	Migraine Pipeline Report Introduction
2.	Migraine Pipeline Report Executive Summary
3.	Migraine Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Migraine Clinical Trial Therapeutics
6.	Migraine Pipeline: Late-Stage Products (Pre-registration)
7.	Migraine Pipeline: Late-Stage Products (Phase III)
8.	Migraine Pipeline: Mid-Stage Products (Phase II)
9.	Migraine Pipeline: Early-Stage Products (Phase I)
10.	Migraine Pipeline Therapeutics Assessment
11.	Inactive Products in the Migraine Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Migraine Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the migraine pipeline therapeutics, reach out @ Migraine Therapeutics

Related Reports

Migraine Epidemiology Forecast

Migraine Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted migraine epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Migraine Market

Migraine Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, among others.

Cluster Headache Market

Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical , among others.

Cluster Headache Clinical Trial Analysis Pipeline

Cluster Headache Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical , among others.

DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn

CONTACT: Contact Us Shruti Thakur... +14699457679